Garrison Point Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Garrison Point Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Hold	9,501	–	–	0.1%	160
2026 Q1	$211K	Hold	9,501	–	–	0.1%	161
2025 Q4	$254K	Sell	9,501 -1,075	-10%	-$25.7K	0.11%	147
2025 Q3	$226K	Hold	10,576	–	–	0.09%	160
2025 Q2	$228K	Hold	10,576	–	–	0.1%	158
2025 Q1	$176K	Hold	10,576	–	–	0.09%	159
2024 Q4	$194K	Hold	10,576	–	–	0.09%	159
2024 Q3	$163K	Buy	+10,576	New	+$176K	0.1%	144
2024 Q2	–	Sell	-10,020	Closed	-$185K	–	144
2024 Q1	$185K	Hold	10,020	–	–	0.12%	148
2023 Q4	$314K	Hold	10,020	–	–	0.22%	112
2023 Q3	$209K	Hold	10,020	–	–	0.16%	139
2023 Q2	$240K	Sell	10,020 -250	-2%	-$5.56K	0.17%	137
2023 Q1	$193K	Hold	10,270	–	–	0.15%	154
2022 Q4	$163K	Hold	10,270	–	–	0.13%	139
2022 Q3	$168K	Hold	10,270	–	–	0.15%	137
2022 Q2	$145K	Buy	10,270 +50	+0.5%	+$933	0.12%	146
2022 Q1	$248K	Hold	10,220	–	–	0.17%	134
2021 Q4	$239K	Buy	+10,220	New	+$206K	0.16%	141
2021 Q1	–	Sell	-4,525	Closed	-$242K	–	142
2020 Q4	$242K	Buy	+4,525	New	+$225K	0.19%	123
2020 Q3	–	Sell	-4,525	Closed	-$219K	–	130
2020 Q2	$219K	Sell	4,525 -250	-5%	-$12K	0.22%	116
2020 Q1	$202K	Sell	4,775 -1,352	-22%	-$55.7K	0.25%	106
2019 Q4	$262K	Hold	6,127	–	–	0.24%	109
2019 Q3	$221K	Buy	+6,127	New	+$186K	0.22%	115

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Garrison Point Advisors's ACAD Position: Q2 2026 in Review

Garrison Point Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 9,501 shares worth $240K. The position accounts for 0.1% of the portfolio, ranked #160.

Garrison Point Advisors first reported a position in ACAD in Q3 2019 and has held it in 23 quarters since. The position peaked at $314K in Q4 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Garrison Point Advisors held 9,501 shares of Acadia Pharmaceuticals worth $240K as of Q2 2026.
Garrison Point Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 0.1% of Garrison Point Advisors's portfolio in Q2 2026, its #160 holding.
Garrison Point Advisors first reported a position in Acadia Pharmaceuticals in Q3 2019 and has held it in 23 quarters since.
Garrison Point Advisors's Acadia Pharmaceuticals position peaked at $314K in Q4 2023.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Garrison Point Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.